KAMADA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,043 ILa | -1.97% |
|
-1.59% | -8.26% |
| 05-08 | Transcript : Kamada Ltd., Q1 2024 Earnings Call, May 08, 2024 | |
| 05-08 | Kamada Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
ETFs positioned on Kamada Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.26% | 318M | |
| -0.89% | 89.46B | |
| +2.76% | 40.74B | |
| -12.32% | 33.03B | |
| +52.41% | 24.68B | |
| -17.39% | 15.12B | |
| -42.45% | 11.64B | |
| -10.48% | 11.79B | |
| +6.14% | 8.9B | |
| -7.72% | 8.22B |
- Stock Market
- Equities
- KMDA Stock
- Funds and ETFs Kamada Ltd.